Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Metformin is associated with survival benefit in pancreatic cancer patients with diabetes: a systematic review and meta-analysis

Published:2017-02-25 Issue:15 Volume:8 Page:25242-25250
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Zhou Ping-Ting¹,Li Bo²,Liu Fu-Rao¹,Zhang Mei-Chao¹,Wang Qian¹,Li Yan-Yan¹,Xu Ci¹,Liu Yuan-Hua³,Yao Yuan⁴,Li Dong¹

Affiliation:

1. Department of Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

2. Department of Bone Tumor Surgery, Changzheng Hospital, Second Military Medical University, Shanghai, China

3. Department of Chemotherapy, Nanjing Medical University Affiliated Cancer Hospital, Cancer Institute of Jiangsu Province, Nanjing, Jiangsu, China

4. Department of Radiation Oncology, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 62 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study;JNCI: Journal of the National Cancer Institute;2024-03-26

2. Metronomic cyclophosphamide and metformin inhibited tumor growth and repopulated tumor-infiltrating lymphocytes in an experimental carcinoma model;BMC Research Notes;2024-01-02

3. Risk of pancreatitis and pancreatic carcinoma for anti-diabetic medications: findings from real-world safety data analysis and systematic review and meta-analysis of randomized controlled trials;Expert Opinion on Drug Safety;2023-11-20

4. Metronomic cyclophosphamide and metformin inhibited tumor growth and repopulated tumor infiltrating lymphocytes in experimental carcinoma model;2023-09-27

5. Diabetes from Exocrine Pancreatic Disease;The Pancreas;2023-08-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3